Vox Markets Logo

Arix Bioscience adds $1.9m to stake in Iterum Therapeutics in $52m private placement

14:40, 17th January 2020
Abraham Darwyne
Company News
TwitterFacebookLinkedIn

Arix Bioscience (ARIX) FOLLOW, the biotech venture capital company, pledged $1.9 million (£1.5 million) as part of a $51.9 million private placement in NASDAQ-listed Iterum Therapeutics.

The investment will add to Arix’s 7.3% stake in Iterum, which was valued at $4.9 million (£3.7 million) a day before the announcement of the private placement.

Iterum Therapeutics develops oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens.

Shares in Arix Bioscience were trading flat at 96.5p during Friday afternoon trading

ARIX price chart

Iterum told investors that the proceeds from the placement will fund continued clinical development of sulopenem, the management of regulatory filings and general working capital.

The securities purchase agreement is to be led by Sarissa Capital Management LP, with new and existing investors, which include RA Capital Management and entities affiliated with certain Iterum board members.

Iterum is selling $51.9 million of 6.5% exchangeable senior notes, and $0.1 million in royalty-linked senior notes.

The agreement is expected to close within five business days of the execution date.

Follow News & Updates from Arix Bioscience here: FOLLOW

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist